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Factor  B,  a  92,000  dalton,  single  chain  glycoprotein,  is  the  major  serine 
protease of the alternative  pathway (AP) of the C system (1);  it is encoded by a 
gene located in the MHC (2).  During activation of the AP, factor B binds to C3b 
in  the  presence of magnesium  and  is  then  cleaved by factor  D,  releasing  the 
33,000 dalton N-terminal fragment Ba. The 60,000 dalton C-terminal fragment, 
Bb, which carries the enzymatic site, is rapidly released upon decay-dissociation 
of the  C3-convertase  C3bBb  (1,  3).  Guinea  pig  Ba  has  been  reported  to  be 
chemotactic, in vitro, for guinea pig polymorphonuclear leukocytes (4). 
Several observations led us to hypothesize that  factor B, and more likely one 
of its  activation  fragments,  could  play  a  role  in  the  control  of growth  and 
maturation of B lymphocytes: (a) factor B is a major constitutive protein synthe- 
sized and secreted by macrophages (reviewed in reference 5), as well as by some 
B lymphocytes (6).  Treatment of macrophages with bacterial LPS increases the 
production of factor B (7); (b) the requirement for macrophages in the polyclonal 
activation of murine B lymphocytes by LPS is still controversial (8).  However, it 
is widely accepted that accessory cells and/or their secreted factors help for an 
optimal  response of B lymphocytes to LPS (9);  (c) finally, LPS, as well as some 
other B cell mitogens,  may activate the AP (10),  thus allowing the cleavage of 
factor  B  by factor  D,  in  the  presence  of C3b,  thereby releasing  its activation 
fragments Bb and Ba in the microenvironment of the cells. 
In the present study we have investigated the action of human factor B and its 
activating enzyme factor D, as well as the activation fragments Bb and Ba on the 
growth  of activated  mouse spleen  B  lymphocytes.  Indeed,  human  and  mouse 
factor  B  display very high  homology in  amino  acid  sequence (11);  moreover, 
murine  factor  B  can  be  cleaved  by human  factor  D.  We  show  that  purified 
fragment Ba is strongly mitogenic for LPS-preactivated B cell blasts, whereas it 
has  no  effect on  the  growth  rates  of Con  A-activated  T  cell  blasts  or  CTL. 
Furthermore,  fragment  Ba was also shown to be a  potent growth factor for in 
vivo activated B cell blasts isolated from unprimed mice of the LPS nonresponder 
C3H/HeJ strain. 
We propose that fragment Ba should be regarded as a B cell stimulatory factor 
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(BSF); up to now, this is the only biological activity that has been reported for 
human Ba. 
Materials and Methods 
Purified Components.  Factor B  (1),  factor D  (12),  and  C3  (13)  were purified from 
human plasma according to the standard procedures, with minor modifications. Factor B 
(20 mg) was cleaved into its fragments Bb and Ba by a 90 rain incubation at 37°C with 
C3 (200 ~g) and factor D (20 #g), in veronal-buffered saline containing 0.012 M MgSO4. 
Factor B, Ba, and Bb were purified by gel filtration on an Ultrogel AcA54 (IBF, Villeneuve 
la  Garenne,  France),  followed by  Fast-protein  liquid  chromatography- (FPLC) anion 
exchange chromatography on a  Mono-Q column (Pharmacia Fine Chemicals,  Uppsala, 
Sweden) equilibrated with 20 mM phosphate buffer, pH 7.2. 
Mice.  C57B1/6,  B10BR,  and  C3H/HeJ  mice of both  sexes were  bred  in  our own 
facilities, and used at 8-12 wk of age. 
Assays.  The assay  for B cell stimulatory factor (BSF) was carried out on:  (a)  LPS- 
preactivated B cell blasts;  anti-Thy-l.2 (HO.13-4-9, a  kind gift of Dr.  Gottlieb, Sloan- 
Kettering Institute for Cancer Research, New York) and C treated mouse spleen cells 
were cultivated with LPS (50 #g/ml; Difco Laboratories Inc., Detroit, MI), in RPMI-1640 
medium (Flow Laboratories Ltd., Irvine, Scotland), containing 10% heat-inactivated FCS 
(Flow Laboratories Ltd.), antibiotics,  2-ME (50 #M,  L-glutamine (2  mM), and sodium 
pyruvate (0.11 mg/mi), as described previously (14). After 18-20 h, living cells, consisting 
of >90% surface Ig-positive cells, were harvested by density centrifugation on Lympho- 
prep (Nyegaard, Oslo, Norway). Cells were extensively washed and subcultured in flat- 
bottomed microtiter plates (Falcon Labware, Oxnard, CA), at 105 cells/ml, in RPMI-1640 
serum-free medium supplemented with antibiotics, human albumin (0.4 mg/ml), transfer- 
rin (0.75 #g/ml),  insulin (2 #g/ml),  2-ME, L-glutamine, and sodium pyruvate. Medium 
and LPS restimulation provided the negative and positive controls, respectively; (b) in 
vivo activated B cell blasts  from unprimed mice of the  LPS-non responder C3H/HeJ 
strain;  spleen  cells  were  treated  with  anti-Thy-l.2 and  complement.  Cells  were  then 
separated on a discontinuous Percoll gradient (Pharmacia Fine Chemicals), from which 
only the cell fraction of density between  1,059 and  1,064  was  collected. Finally, low 
density cells were extensively washed and subcultured in round-bottomed microtiter plates 
(Falcon Labware), at 3 ×  10  ~ cells/ml, in RPMI-1640 serum-free medium supplemented 
as described above. 
T  cell growth  factor (TCGF) assays  were performed on  T  cell blasts  (10  s cells/mi) 
obtained from Con A-stimulated cultures, and on a TCGF-dependent cytotoxic T  cell 
line,  as  described  (14).  Medium  and  a  standard  preparation  of TCGF  provided  the 
negative and positive controls, respectively. 
In all assays,  complement peptides were titrated in a  twofold serial dilution into the 
assay wells; proliferation was assayed on day 2 after subculture, cells were pulsed with 
[3H]TdR (1 #Ci/culture) for 6 h, harvested, and counted; results are expressed as the cpm 
per culture. 
Results 
Effects of Cleavage of Factor B by Factor D on Proliferation  of LPS-preactivated  B 
Cell Blasts.  Factor B was added at a  final concentration of 25 #g/ml, to serum- 
free cultures, in which factor D  was titrated in a  twofold serial dilution starting 
from  16  #g/mi.  LPS-preactivated B  cell blasts  did  not maintain  growth  when 
recuitured in serum-free medium alone (660 _  110 cpm), but they did so when 
restimulated by LPS (15,328 __. 2,101  cpm). 
As shown  in  Fig.  1,  the addition  of factor D  to cultures containing factor B 
strikingly enhanced  [3H]thymidine  uptake.  A  plateau  level of maximum  [~H]- 
thymidine uptake was seen for concentrations of factor D  ranging from 16 to 4 
#g/ml (30,971  --- 2,370 cpm). Background level was reached for concentrations PRAZ  AND  RUUTH.  BRIEF  DEFINITIVE  REPORT  1351 
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FIGURE  1.  Effects of cleavage of factor B by factor D on proliferation of LPS-preactivated 
B cell blasts. Factor D was tested either alone (F-I) or in the presence of 25 pg/ml of factor B 
(.), in a  1:2 serial dilution starting at 16 #g/m]. Control responses to LPS (0), factor B alone 
(~),  or  medium  (O)  were  15,328  +  2,101  cpm,  660  +  110  cpm,  and  594  +-  163  cpm, 
respectively. 
lower than  1 pg/ml.  By contrast, factor D alone, even at high concentrations, 
did not significantly enhance [3H]thymidine uptake by LPS-preactivated B cell 
blasts; proliferation obtained in presence of factor B alone (594 +  163 cpm) was 
also comparable to the medium control. 
Effects of Fragment Ba on Proliferation of Activated B Cells.  Since factor B had 
to be cleaved by factor D to exhibit growth-promoting activity, we have investi- 
gated  the  effects of its  activation  fragments  Ba  and  Bb  on  proliferation  of 
activated B cells. Serial dilutions of factor B, Bb, and Ba were added to serum- 
free cultures of LPS-preactivated B cell blasts. Complement peptides concentra- 
tions are expressed as molarity (M), allowing direct comparison of the responses 
to B, Bb, and Ba; 2 #M of factor B, Bb, and Ba corresponding to 180,  120, and 
60 pg/ml, respectively. 
As shown in Fig. 2 a, the addition of 60 #g/ml (2 pM) of highly purified Ba to 
serum-free cultures of LPS-preactivated B  cell blasts  increased [3H]thymidine 
uptake up to nine times the background; a linear dose-response was obtained for 
Ba concentrations ranging from 3 to 60  #g/ml.  By contrast, neither factor B, 
nor its fragment Bb, show any growth-promoting activity (Fig. 2 a). The response 
to Ba reaches maximum levels for concentrations above 120 ug/ml (4 pM, Fig. 
2b). 
In order to determine if the growth-supporting activity of Ba was restricted to 
B cells preactivated by LPS, or if it might as well act on other activated B cells, 
we have investigated its effect on in vivo, activated B cell blasts obtained from 
unprimed mice of the LPS-nonresponder C3H/HeJ strain. Fig. 2 c shows that Ba 
has the ability to maintain growth of low density B cells of unprimed C3H/HeJ 
mice; moreover, the magnitude and the dose-dependency of the response are 
comparable to those obtained with the LPS-preactivated B cell blasts. 
Fragment Ba Has No TCGF-like Activity.  The cellular specificity of the growth- 
supporting activity of Ba was further probed by investigating its effect on the 
growth of T  lymphocytes. We used both TCGF-dependent CTL cells and Con 1352  PRAZ  AND  RUUTH.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  2.  Effects of fragment Ba on B cell blasts proliferation. Purified factor B (O), Bb (V), 
and Ba (A) were added to LPS-preactivated B cell blast cultures in a  1:2 serial dilution starting 
at 2  tiM (a) or 8  I~M (b), with LPS restimulation (0) and medium (O) as controls. (c) Ba was 
added to cultures of in vivo, activated B  cell blasts from unprimed C3H/HeJ  mice; Ba  1:2 
serial dilution started at 2 tiM. Note the change of scale in c. 
TABLE  ] 
Fragment Ba Has No TCGF-Iike Activity 
[SH]Thymidine incorporation (cpm ± SD) 
Cells cultured 
Medium  TCGF-CM  Ba (60 ttg/ml) 
CTL cells  4,034 ±  340  352,860 ±  35,611  4,345 4- 936 
Con A-activated T cells  945 ±  130  125.267 ± 9,580  1,011  ± 224 
Con A-activated T cells and TCGF-dependent CTL cells were cultivated at l0  s cells/ml in the presence or absence 
of 60 t~g/ml of purified Ba, with TCGF-CM as positive control. Results are expressed as the average cpm of six 
replicate cultures + SD. 
A-activated T  cells as  responder cells.  Highly purified  Ba  was added  to  the 
cultures at a final concentration of 60 #g/ml, which gave substantial proliferative 
responses with activated B cell blasts. 
As shown in Table I, Ba failed to maintain proliferation of TCGF-reactive T 
cells; [3H]thymidine incorporation was identical whether or not Ba was added to 
the medium,  whereas the addition  of conditioned medium containing TCGF 
activity supported the growth of both CTL cells and Con A-activated T  cells 
very efficiently. 
Discussion 
The results presented here describe the first biological activity of fragment Ba 
of the human alternative complement pathway as a B cell stimulatory factor. We 
show that highly purified fragment Ba supports growth of in vitro, LPS-preacti- 
vated  B  cell blasts;  moreover, Ba  also maintains proliferation  of the in  vivo, 
activated B cell blasts from unprimed mice of the LPS-nonresponder C3H/HeJ 
strain, showing that the growth-supporting activity of Ba is not restricted to LPS- 
preactivated B cell blasts. By contrast, Ba has no effect on proliferation of TCGF- 
reactive T  cells. PRAZ  AND  RUUTH.  BRIEF  DEFINITIVE  REPORT  1353 
Miyama et al. reported that treatment of macrophages with LPS considerably 
increases synthesis and secretion of factor B (7).  Furthermore, since both factor 
D and C3 are synthesized by macrophages (reviewed in reference 5), AP activa- 
tion by LPS may occur in the microenvironment of the LPS-activated cells. In 
fact, we could show that the addition of factor B  and factor D  to serum-free 
cultures containing macrophages supported growth of the LPS-preactivated B 
cell blasts very efficiently. Since neither factor B alone nor factor D alone had 
any significant effect, we conclude that the growth-supporting activity is not due 
to a possible contamination of the protein preparations by LPS or other mitogens, 
but is more likely mediated by one of the activation fragments released during 
the cleavage of factor D. We have established that fragment Ba has the ability to 
support growth of the LPS-preactivated B cell blasts, it is therefore tempting to 
speculate that Ba is a physiological mediator for B cell activation by LPS. 
It has been reported that fragment Ba generated during AP activation is a 
short-lived product (14),  in that the C-terminal arginine (Arg) and lysine (Lys) 
residues are rapidly released by a serum carboxypeptidase B. Similarly, both the 
anaphylatoxins C3a and C5a have a C-terminal Arg that modulates the expression 
of their biological activities. The role of the two C-terminal basic residues of Ba 
in  the control of the B  cell growth has not been formally investigated.  Since 
cleavage of factor B has been done in the absence of carboxypeptidase B inhibitor, 
it is most likely that purified fragment Ba preparations contain a mixture of its 
native form and its deSArg and deSArg-Lys  fragments. In fact, it was necessary to 
add  120  t~g]ml of purified  Ba  to  LPS-preactivated B  cell blasts  to  reach the 
plateau level of maximal proliferative response, whereas cleavage of 25 ~g/ml of 
factor B by high concentrations of factor D was enough. Under such experimental 
conditions, extensive cleavage of factor B would yield a maximal concentration 
of 8 ~g/ml of Ba; this indicates that Ba generated through cleavage of factor B 
in the cultures is more efficient than purified Ba itself, suggesting that the native 
form of Ba, which is progressively released in the microenvironment of the cells, 
is more active than fragments that have lost Lys and/or Arg. 
Summary 
We  have  investigated the  effects of cleavage of factor  B  by  its  activating 
enzyme, factor D, as well as its activation fragments Bb and Ba, on the growth 
of mouse spleen B lymphocytes preactivated by LPS. Neither factor B nor factor 
D  show any growth-supporting activity when tested alone. The coaddition of 
factor B and factor D  to serum-free cultures of LPS-preactivated B cell blasts 
increased the proliferation of the responding cells up to the level obtained by 
restimulation with LPS. Such growth-supporting activity was shown to be medi- 
ated by Ba, whereas Bb did not show any significant effect. Furthermore, this 
effect was not restricted to the LPS-preactivated B  cell blasts;  in  fact, Ba also 
supported the growth of in vivo, activated B cell blasts of unprimed mice of the 
LPS-nonresponder C3H/HeJ strain. In contrast, Ba did not maintain growth of 
Con A-activated T  cells or TCGF-dependent CTL cells. 
Taken together, these results describe the first biological activity of human Ba 
as a B cell stimulatory factor. 1354  PRAZ  AND  RUUTH.  BRIEF  DEFINITIVE REPORT 
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